Two-Pronged attack on tough leukemia shows promise
NCT ID NCT06308588
Summary
This study is testing whether combining two drugs, blinatumomab and asciminib, can help control a fast-growing blood cancer called Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). It will involve about 40 adults and teenagers, including those newly diagnosed and those whose cancer has returned or resisted treatment. The main goals are to find a safe and effective dose and to see if the treatment can eliminate very small amounts of leftover cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.